RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study (Q33499541)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 September 2009

Language	Label	Description	Also known as
English	RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study	scientific article published on 2 September 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

0 references

1 reference

based on heuristic

inferred from title

19

object named as

Ulrich Bogdahn

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

20

object named as

Peter Hau

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Martin Proescholdt

14

object named as

Martin Proescholdt

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Alexander Brawanski

9

object named as

Alexander Brawanski

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

object named as

Monika Hegi

18

0 references

author name string

Christoph P Beier

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Christina Schmid

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Thierry Gorlia

3

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Christine Kleinletzenberger

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Dagmar Beier

5

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Oliver Grauer

6

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Andreas Steinbrecher

7

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Birgit Hirschmann

8

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Christopher Dietmaier

10

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Tanja Jauch-Worley

11

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Oliver Kölbl

12

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Torsten Pietsch

13

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Petra Rümmele

15

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Armin Muigg

16

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Günther Stockhammer

17

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

language of work or name

0 references

publication date

2 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

308

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Temozolomide preferentially depletes cancer stem cells in glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

Cutaneous reactions to chemotherapy drugs: the art of consultation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

Chemotherapy response criteria in malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749868

21 June 2018

Chemosensitivity of glioma cells in vitro: a meta analysis.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-308

21 January 2018

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-308

21 January 2018

Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-308

21 January 2018

Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-308

21 January 2018

Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-308

21 January 2018

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-308

21 January 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-308

21 January 2018

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-308

21 January 2018

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-308

21 January 2018

Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19725960

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model

1 reference

https://pubmed.ncbi.nlm.nih.gov/19725960

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model

1 reference

https://pubmed.ncbi.nlm.nih.gov/19725960

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme

1 reference

https://pubmed.ncbi.nlm.nih.gov/19725960

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19725960

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-9-308

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33499541&oldid=2195420076"